Keep up to date with the latest news and updates from MorphCryst Consulting and from the wider industry.
Establishing if your newly discovered drug substance solid is polymorphic is a regulatory requirement as part of new drug approval submission. This is captured as part of the chemistry, manufacturing and controls (CMC) section of an NDA for a drug substance, together with a whole host of topics.
The ability to produce a salt of a drug substance with counter ions relies on the new chemical entity, NCE, or API containing functionalities which allow proton transfer to take place. Alternatively, cocrystal formation utilises hydrogen bonding and Van der Waals interactions between suitable moieties in the drug substance and a conformer.
You have identified and selected the structure of your compound from medicinal chemistry investigations as a therapeutic agent and is a new chemical entity, NCE, and have also generated material with which you are collecting pharmacokinetic and toxicological information to support your drug compound.
For a newly discovered solid chemical entity as an API, one of the characteristics to establish is the aqueous solubility. Another property which is also used to define a drug substance is the melting point. For a substance to melt, energy is required; this process is described as endothermic. This is a thermodynamic property of the solid and is termed the enthalpy.
A concern from a regulatory stance, BP and Ph. Er., with progressing a potential drug molecule sulfonate salt into clinical and drug development is the formation and presence of mutagenic alkyl sulfonate impurities produced when the salt formation or salt recrystallisation was conducted in alcohol solvents.
Use this form to contact us. We'll get back to you as soon as possible.
© 2025 Morph Cryst Consulting - Company no. 16616278
All rights reserved.